Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study Group
Purpose
This retrospective cohort study aimed to determine the predictive relevance of clinical characteristics, additional cytogenetic aberrations, and cKIT and RAS mutations, as well as to evaluate whether specific treatment elements were associated with outcomes in pediatric t(8;21)-positive patients with acute myeloid leukemia (AML).
Patients and Methods
Karyotypes of 916 pediatric patients with t(8;21)-AML were reviewed for the presence of additional cytogenetic aberrations, and 228 samples were screened for presence of cKIT and RAS mutations. Multivariable regression models were used to assess the relevance of anthracyclines, cytarabine, and etoposide during induction and overall treatment. End points were the probability of achieving complete remission, cumulative incidence of relapse (CIR), probability of event-free survival, and probability of overall survival.
Results
Of 838 patients included in final analyses, 92% achieved complete remission. The 5-year overall survival, event-free survival, and CIR were 74%, 58%, and 26%, respectively. cKIT mutations and RAS mutations were not significantly associated with outcome. Patients with deletions of chromosome arm 9q [del(9q); n = 104] had a lower probability of complete remission (P = .01). Gain of chromosome 4 (+4; n = 21) was associated with inferior CIR and survival (P < .01). Anthracycline doses greater than 150 mg/m2 and etoposide doses greater than 500 mg/m2 in the first induction course and high-dose cytarabine 3 g/m2 during induction were associated with better outcomes on various end points. Cumulative doses of cytarabine greater than 30 g/m2 and etoposide greater than 1,500 mg/m2 were associated with lower CIR rates and better probability of event-free survival.
Conclusion
Pediatric patients with t(8;21)-AML and additional del(9q) or additional +4 might not be considered at good risk. Patients with t(8;21)-AML likely benefit from protocols that have high doses of anthracyclines, etoposide, and cytarabine during induction, as well as from protocols comprising cumulative high doses of cytarabine and etoposide.
Top-30
Journals
|
1
2
3
4
5
|
|
|
Leukemia and Lymphoma
5 publications, 6.67%
|
|
|
International Journal of Molecular Sciences
4 publications, 5.33%
|
|
|
Cancers
3 publications, 4%
|
|
|
BMC Cancer
3 publications, 4%
|
|
|
British Journal of Haematology
3 publications, 4%
|
|
|
Pediatric Blood and Cancer
3 publications, 4%
|
|
|
Blood
3 publications, 4%
|
|
|
Scientific Reports
2 publications, 2.67%
|
|
|
Leukemia Research
2 publications, 2.67%
|
|
|
Expert Review of Anticancer Therapy
2 publications, 2.67%
|
|
|
Journal of Clinical Oncology
2 publications, 2.67%
|
|
|
Pediatric Hematology/Oncology and Immunopathology
2 publications, 2.67%
|
|
|
Oncotarget
1 publication, 1.33%
|
|
|
Oncology Reports
1 publication, 1.33%
|
|
|
Journal of Pediatric Hematology/Oncology
1 publication, 1.33%
|
|
|
Medicine (United States)
1 publication, 1.33%
|
|
|
Genes
1 publication, 1.33%
|
|
|
Biomedicines
1 publication, 1.33%
|
|
|
Frontiers in Genetics
1 publication, 1.33%
|
|
|
Pathology and Oncology Research
1 publication, 1.33%
|
|
|
Current Oncology Reports
1 publication, 1.33%
|
|
|
Clinical Pharmacokinetics
1 publication, 1.33%
|
|
|
International Journal of Hematology
1 publication, 1.33%
|
|
|
Leukemia
1 publication, 1.33%
|
|
|
Paediatric Drugs
1 publication, 1.33%
|
|
|
Cancer and Metastasis Reviews
1 publication, 1.33%
|
|
|
Seminars in Cancer Biology
1 publication, 1.33%
|
|
|
Gene
1 publication, 1.33%
|
|
|
Biology of Blood and Marrow Transplantation
1 publication, 1.33%
|
|
|
1
2
3
4
5
|
Publishers
|
2
4
6
8
10
12
14
|
|
|
Springer Nature
14 publications, 18.67%
|
|
|
MDPI
11 publications, 14.67%
|
|
|
Taylor & Francis
10 publications, 13.33%
|
|
|
Wiley
8 publications, 10.67%
|
|
|
Elsevier
7 publications, 9.33%
|
|
|
American Society of Hematology
5 publications, 6.67%
|
|
|
Spandidos Publications
2 publications, 2.67%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
2 publications, 2.67%
|
|
|
American Association for Cancer Research (AACR)
2 publications, 2.67%
|
|
|
American Society of Clinical Oncology (ASCO)
2 publications, 2.67%
|
|
|
Fund Doctors, Innovations, Science for Children
2 publications, 2.67%
|
|
|
Impact Journals
1 publication, 1.33%
|
|
|
Frontiers Media S.A.
1 publication, 1.33%
|
|
|
Pleiades Publishing
1 publication, 1.33%
|
|
|
The Korean Society of Hematology
1 publication, 1.33%
|
|
|
Annual Reviews
1 publication, 1.33%
|
|
|
Practical Medicine Publishing House
1 publication, 1.33%
|
|
|
IntechOpen
1 publication, 1.33%
|
|
|
AME Publishing Company
1 publication, 1.33%
|
|
|
2
4
6
8
10
12
14
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.